Topic:

Infectious Diseases

Latest Headlines

Latest Headlines

GSK's rotavirus vaccine selected for British program

British health officials selected GlaxoSmithKline's Rotarix vaccine for the country's first routine rotavirus immunization program.

GSK reports lackluster PhIII malaria vaccine data

A GlaxoSmithKline malaria vaccine posted surprisingly lackluster results in a Phase III trial, putting a damper on solid results from previous studies. The vaccine against the mosquito-borne illness proved only 30% effective when given to African children in a clinical trial.

Gates Foundation funds tuberculosis vaccine research

Continuing a streak of donations to the field of vaccine research and biotech in general, the Bill & Melinda Gates Foundation granted $100,000 to an AgResearch scientist for research into a new tuberculosis vaccination method.

HIV vaccine shows significant immunity boost in human trials

Good news out of Canada in the search for an HIV vaccine: Scientists announced a vaccine candidate showed no adverse effects and significantly boosted immunity in human trials.

Health officials clash over whether to scrap malaria program

Health officials have clashed over the effectiveness of a pricey malaria program intended to provide cheap drugs for poor patients.

Mumps vaccine succumbs to face-to-face contact

A recent study shows close, repeated contact with a person with mumps can overwhelm the mumps vaccine.

Oral vaccine relies on 'good bacteria'

Oral vaccines prove an alluring alternative to painful shots, and scientists at Royal Holloway, University of London, are pioneering a new method of oral vaccination using probiotic spores--"good bacteria." The method could help boost immunity to tuberculosis and influenza, as well as prevent C. difficile.

CDC green-lights GSK's meningitis vaccine for at-risk infants

A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection.

Genocea wraps up $30M round for T-cell vaccines

Genocea Biosciences has raised $30 million in a Series C financing round to advance its T-cell vaccines for infectious diseases. With the close of this financing round, the clinical-stage company has landed a total of $76 million in equity financing to date.

GSK, Aeras partner for TB vaccine trial

GlaxoSmithKline ($GSK) will work with nonprofit biotech Aeras to test a tuberculosis vaccine in Africa and India, making headway in developing new ways to prevent the disease.